Acrivon Reports Third Quarter 2026 Financial Results and Business Highlights
Globe Newswire•16/11/2026•16:05 ET
0
Key Highlights
- ➤Cash $77.8 million expected to fund operations into fourth quarter of 2027
- ➤ACR-525 acquired as Phase 2-ready, highly selective JAK1 inhibitor for EoE
- ➤ACR-2316 showed confirmed responses and long-lasting benefit in AP3-predicted tumors
- ➤ACR-368 Phase 2b interim analysis in serous endometrial cancer expected fourth quarter 2026
- ➤Third-quarter net loss $17.9 million versus $18.2 million year over year
Expert Statements
Peter Blume-Jensen, Chief executive officer, president, and co-founder of Acrivon Therapeutics
“We have had transformative progress this year, including the strategic expansion into immunology and inflammation and the positive clinical results in tumor types predicted sensitive by AP3 to our internally developed, first-in-class WEE1/PKMYT1 inhibitor ACR-2316, laying the foundation for multiple upcoming value-inflection milestones”
Peter Blume-Jensen, Chief executive officer, president, and co-founder of Acrivon Therapeutics
“I&I is particularly well-suited for our AP3 precision medicine approach. We acquired ACR-525 after identifying it as a potentially best-in-class JAK1 inhibitor using our AI-driven AP3 platform for extensive profiling head-to-head against approved JAK inhibitors and dupilumab. Based on this, eosinophilic esophagitis is targeted as an attractive first indication for this Phase 2-ready, oral, highly selective JAK1 inhibitor. The transaction also included a differentiated preclinical PKCθ program for T-cell driven I&I disorders. Additionally, we remain on track for the prespecified interim analysis of the ACR-368 Phase 2 registrational-intent trial. For ACR-2316, our highly differentiated, first-in-class WEE1/PKMYT1 inhibitor in Phase 1/2 dose expansion, we have observed a very favorable safety profile and exceptionally long-lasting clinical benefit across AP3 predicted tumors already during dose escalation. Of note, these include heavily pretreated lung cancers where several patients are on treatment for over 73 weeks now, and where we also have a confirmed complete response. Details of these exciting data will be presented by Dr. Tim Yap as a late-breaking oral plenary presentation at the upcoming Tri-Meeting. ACR-2316 will also be tested as single agent in pancreatic ductal adenocarcinoma based on public data showing WEE1 is synthetic lethal in K-Ras & p53 mutated context. Similar to ACR-368, we have shown that ACR-2316 has strong synergy with immune checkpoint inhibitors and Topo1 inhibitors, providing for attractive combination opportunities. Finally, we also nominated a potential first-in-class, oral CDK11 inhibitor, ACR-7280, identified through the AP3 platform, to advance into IND-enabling studies and be developed in the AP3-predicted tumor type AML.”
Immunology and inflammation (I&I) established as a second strategic pillar for company which is particularly well-suited for its AP3 precision medicine approach
AI-driven AP3 platform was used for profiling against approved JAK inhibitors to identify recently acquired ACR-525, a Phase 2-ready, potentially best-in-class, highly selective JAK1 inhibitor, and a differentiated preclinical PKCθ program
Get started
Create a free account to read the full story.
